Literature DB >> 11289524

Failure of Mycoplasma pneumoniae infection to confer protection against Mycoplasma genitalium: observations from a mouse model.

D Taylor-Robinson1, P M Furr1.   

Abstract

Mycoplasma pneumoniae and M. genitalium are genomically distinct but share antigens that induce some serological cross-reactivity. Therefore, the possibility that M. pneumoniae infection of the human respiratory tract might provide immunity to M. genitalium infection of the genital tract was considered. Because of the difficulty of assessing this proposition in man, it was evaluated experimentally in a mouse model. Female BALB/c mice were susceptible to infection of the vagina with M. pneumoniae, whereas those infected previously in the oropharynx with M. pneumoniae were completely immune to infection of the vagina with this mycoplasma. However, all mice with such a respiratory tract infection were susceptible to infection of the vagina with M. genitalium. The findings suggest that an M. pneumoniae infection of the human respiratory tract is unlikely to influence infection of the genital tract by M. genitalium.

Entities:  

Mesh:

Year:  2001        PMID: 11289524     DOI: 10.1099/0022-1317-50-4-383

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  3 in total

Review 1.  Mycoplasma genitalium: from Chrysalis to multicolored butterfly.

Authors:  David Taylor-Robinson; Jørgen Skov Jensen
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Identification and characterization of immunogenic proteins of mycoplasma genitalium.

Authors:  Helle Friis Svenstrup; Jørgen Skov Jensen; Kris Gevaert; Svend Birkelund; Gunna Christiansen
Journal:  Clin Vaccine Immunol       Date:  2006-08

3.  Mycoplasma genitalium rapidly disseminates to the upper reproductive tracts and knees of female mice following vaginal inoculation.

Authors:  Chris L McGowin; Rae Ann Spagnuolo; Richard B Pyles
Journal:  Infect Immun       Date:  2009-12-07       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.